SG11202100116TA - Method of using a gip/glp1 co-agonist for diabetes - Google Patents

Method of using a gip/glp1 co-agonist for diabetes

Info

Publication number
SG11202100116TA
SG11202100116TA SG11202100116TA SG11202100116TA SG11202100116TA SG 11202100116T A SG11202100116T A SG 11202100116TA SG 11202100116T A SG11202100116T A SG 11202100116TA SG 11202100116T A SG11202100116T A SG 11202100116TA SG 11202100116T A SG11202100116T A SG 11202100116TA
Authority
SG
Singapore
Prior art keywords
glp1
gip
agonist
diabetes
Prior art date
Application number
SG11202100116TA
Other languages
English (en)
Inventor
Jorge Alsina-Fernandez
Over Cabrera
Tamer Coskun
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG11202100116TA publication Critical patent/SG11202100116TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG11202100116TA 2018-07-23 2019-07-22 Method of using a gip/glp1 co-agonist for diabetes SG11202100116TA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862702180P 2018-07-23 2018-07-23
US201862730562P 2018-09-13 2018-09-13
US201862740640P 2018-10-03 2018-10-03
PCT/US2019/042824 WO2020023388A1 (fr) 2018-07-23 2019-07-22 Procédé d'utilisation d'un co-agoniste de gip/glp1 contre le diabète

Publications (1)

Publication Number Publication Date
SG11202100116TA true SG11202100116TA (en) 2021-02-25

Family

ID=67544389

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100116TA SG11202100116TA (en) 2018-07-23 2019-07-22 Method of using a gip/glp1 co-agonist for diabetes

Country Status (13)

Country Link
US (1) US20230293638A1 (fr)
EP (1) EP3826662A1 (fr)
JP (3) JP2021530544A (fr)
KR (1) KR20210024081A (fr)
CN (1) CN112469431A (fr)
AU (1) AU2019309798A1 (fr)
BR (1) BR112020026020A2 (fr)
CA (1) CA3107108A1 (fr)
IL (2) IL280159B2 (fr)
MA (1) MA53378A (fr)
MX (1) MX2021000792A (fr)
SG (1) SG11202100116TA (fr)
WO (1) WO2020023388A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202216746A (zh) 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型glp-1/gip雙重促效劑
IL299701A (en) 2020-07-22 2023-03-01 Novo Nordisk As GLP-1 and GIP receptor co-agonists suitable for oral administration
IL301109A (en) 2020-10-17 2023-05-01 Sun Pharmaceutical Ind Ltd Dual GLP-1/GIP agonists
CA3208873A1 (fr) * 2021-02-17 2022-08-25 Mathijs Christiaan Michael BUNCK Procedes therapeutiques agonistes doubles gip/glp1
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
CN116854805B (zh) * 2023-09-05 2023-12-15 杭州湃肽生化科技有限公司 替尔泊肽的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX362527B (es) * 2011-05-13 2019-01-23 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
KR102184241B1 (ko) 2012-05-03 2020-12-01 질랜드 파마 에이/에스 Gip-glp-1 이원 작용제 화합물 및 방법
WO2015022420A1 (fr) * 2013-08-16 2015-02-19 Medimmune Limited Agonistes doubles de récepteur de gip et glp-1 pour le traitement du diabète
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
US20170112897A1 (en) * 2015-10-23 2017-04-27 Cedars-Sinai Medical Center Methods for treating brain insulin resistance
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
BR112020026671A2 (pt) * 2018-07-23 2021-04-06 Eli Lilly And Company Compostos coagonistas de gip/glp1

Also Published As

Publication number Publication date
CN112469431A (zh) 2021-03-09
EP3826662A1 (fr) 2021-06-02
KR20210024081A (ko) 2021-03-04
IL280159B1 (en) 2024-01-01
CA3107108A1 (fr) 2020-01-30
US20230293638A1 (en) 2023-09-21
MX2021000792A (es) 2021-06-15
MA53378A (fr) 2021-06-02
JP2021530544A (ja) 2021-11-11
AU2019309798A1 (en) 2021-02-11
BR112020026020A2 (pt) 2021-03-23
WO2020023388A1 (fr) 2020-01-30
JP2022177118A (ja) 2022-11-30
IL280159A (en) 2021-03-01
JP2024056852A (ja) 2024-04-23
IL308674A (en) 2024-01-01
IL280159B2 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
IL279827A (en) GIP/GLP1 co-agonist compounds
IL280159A (en) Methods of using a GIP/GLP1 co-agonist for diabetes
IL280258A (en) Methods of using GIP/GLP1 co-agonists for therapy
IL284446A (en) A method for preparing a dual gip/glp1 agonist
EP3815144C0 (fr) Procédé de fabrication d'un appareil d'affichage
GB201915444D0 (en) Method of using a blockchain
PT3766255T (pt) Método para obter informações sobre uma luminária
GB201805954D0 (en) A method
GB201804627D0 (en) A method of communicating
HK1244323A1 (zh) 裝飾鐘錶部件的方法
EP3776213A4 (fr) Procédé de correction d'erreurs d'un processeur
GB2582844B (en) Method of assembling a structure
SG11202105311VA (en) Method of identifying a structure
GB201902908D0 (en) Method of using a blockchain
SG11202106014QA (en) A method for treating lipid materials
GB2576886B (en) A method of analysing images
IL280423A (en) A method for identifying protein intermediates
SG11202105280QA (en) Method of identifying a structure
SG11202100009YA (en) A method of detecting hfmd
GB201817935D0 (en) Method of replacing a module
GB201813722D0 (en) A method
ZA202006375B (en) A method of carbonizate purification
HK1247889A1 (zh) 用於輥壓鐘錶主發條的方法
GB201813730D0 (en) A method
GB201807855D0 (en) Method for fabricating a component of an abatement apparatus